Manufacturing

Articles

In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.

Poseida Therapeutics and Takeda Partner to Develop Non-Viral In-Vivo Gene Therapy Programs

MilliporeSigma announced the opening of its second Carlsbad, California-based facility, which doubles production capacity to support commercial and industrial manufacturing of viral vectors. 

MilliporeSigma Completes $110-Million Contract Development Manufacturing Facility for Gene Therapy

The collaboration between Intellia and SparingVision will work to develop genomic medicines for ocular diseases.

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Avid Bioservices is building a viral vector development and manufacturing facility near its existing biologics manufacturing facility in California. 

Avid Bioservices Expands into Viral Vector Development and Manufacturing Services

Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.

Pfizer Agrees to License Agreement with Voyager Therapeutics

New excipients for protein-based drug products reduce viscosity while maintaining protein stability.

MilliporeSigma Launches Excipient Platform for Protein-Based Therapies

Celularity and Oncternal’s collaboration will focus on therapeutics targeting Orphan Receptor 1, which is linked to aggression and survival in solid tumor cells.

Celularity and Oncternal Therapeutics to Research Placental-Derived Cellular Therapies

Novartis’ acquisition of Arctos Medical could lead to significant advancements in optogenetic therapies for patients with vision loss.

Novartis Acquires Arctos Medical, Expanding Optogenetics Profile

AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.

AGC Bio Boosts Manufacturing Capacity for pDNA and mRNA at Heidelberg Facility

Aptamer Group and Bio-Works Technologies are partnering up to develop a new affinity resin for improved purification and scale-up of gene therapy vectors. 

Manufacturing, Gene Therapies